Immunotherapy of Cancer by Targeting Regulatory T cells

Chen, Bo-Jin; Zhao, Jingwen; Zhang, Dahong; Ai-hong, Zheng; Wu, Guoqing

doi:10.1016/j.intimp.2021.108469

Cited by 61 publications

(44 citation statements)

References 124 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The released cytokines associated with the type of immune cells in the tumor were also analyzed in this study. While IL-10 is an anti-inflammatory cytokine-related to Treg function, IFN-γ is a pro-inflammatory cytokine related to CTL function ( 38 , 39 ). The increased percentage of activated CD8 + T cells and Tregs cells in the tumors of the combination treatments paralleled the enhanced PD1 expression in these cells in this study.…”

Section: Discussionmentioning

confidence: 99%

The long multi-epitope peptide vaccine combined with adjuvants improved the therapeutic effects in a glioblastoma mouse model

Tran

Kim²,

Kim³

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Emerging data have suggested that single short peptides have limited success as a cancer vaccine; however, extending the short peptides into longer multi-epitope peptides overcame the immune tolerance and induced an immune response. Moreover, the combination of adjuvants such as lenalidomide and anti-programmed cell death protein 1 (PD1) with a peptide vaccine showed potential vaccine effects in previous studies. Therefore, the effects of a long multi-epitope peptide vaccine in combination with lenalidomide and anti-PD1 were analyzed in this study. Long multi-epitope peptides from two MHCI peptides (BIRC597-104 and EphA2682-689) and the pan-human leukocyte antigen-DR isotype (HLA-DR) binding epitope (PADRE) were synthesized. The therapeutic effects of long multi-epitope peptides in combination with lenalidomide and anti-PD1 were confirmed in the murine GL261 intracranial glioma model. Immune cells’ distribution and responses to the long multi-epitope peptides in combination with these adjuvants were also estimated in the spleens, lymph nodes, and tumor tissues. The difference between long multi-epitope peptides and a cocktail of multi-epitope peptides combined with lenalidomide and anti-PD1 was also clarified. As a result, long multi-epitope peptides combined with lenalidomide and anti-PD1 prolonged the survival of mice according to the suppression of tumor growth in an intracranial mouse model. While long multi-epitope peptides combined with these adjuvants enhanced the percentages of activated and memory effector CD8+ T cells, the increase in percentages of regulatory T cells (Tregs) was observed in a cocktail of multi-epitope peptides combined with lenalidomide and anti-PD1 group in the tumors. Long multi-epitope peptides combined with these adjuvants also enhanced the function of immune cells according to the enhanced pro-inflammatory cytokines and cytotoxicity against GL261 cells in ex vivo. In conclusion, long multi-epitope peptides composed of MHCI peptides, BIRC5 and EphA2, and the MHCII peptide, PADRE, in combination with lenalidomide and anti-PD1 has the potential to improve the therapeutic effects of a vaccine against GBM.

show abstract

Section: Discussionmentioning

confidence: 99%

The long multi-epitope peptide vaccine combined with adjuvants improved the therapeutic effects in a glioblastoma mouse model

Tran

Kim²,

Kim³

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…The TMV vaccine was transported to the basolateral side by IECs, and DCs captured and effectively cross-presented TMV-derived antigens to activate CD8 + T cells. In malignant tumors, Tregs aid in the immune escape of tumor cells so that the patient's immune system is considerably less effective in fighting the tumor [ 168 ]. Parenky et al also extracted TMV from mouse prostate cancer cells as an oral tumor vaccine [ 169 ].…”

Section: Tumor-derived Extracellular Vesicles (Tevs)mentioning

confidence: 99%

Engineered tumor cell-derived vaccines against cancer: The art of combating poison with poison

Zhang

Cui

Zhang

et al. 2023

Bioactive Materials

View full text Add to dashboard Cite

“…In addition, analysis of Tregs isolated from human breast cancer lesions demonstrated an increased percentage of Tregs as compared to those isolated from normal breast tissue [ 52 ]. Clinical studies suggest that the intra-tumoral Tregs are also highly proliferative and show increased surface expression of T cell antigen CD25, programmed cell death protein 1 (PD-1) and CTLA-4 [ 53 ].…”

Section: Characteristics Of Tumor-specific Regulatory T Cellsmentioning

confidence: 99%

Implications of regulatory T cells in anti-cancer immunity: from pathogenesis to therapeutics

Dwivedi

Tiwari

Kemp

et al. 2022

Heliyon

View full text Add to dashboard Cite

Immunotherapy of Cancer by Targeting Regulatory T cells

Cited by 61 publications

References 124 publications

The long multi-epitope peptide vaccine combined with adjuvants improved the therapeutic effects in a glioblastoma mouse model

The long multi-epitope peptide vaccine combined with adjuvants improved the therapeutic effects in a glioblastoma mouse model

Engineered tumor cell-derived vaccines against cancer: The art of combating poison with poison

Implications of regulatory T cells in anti-cancer immunity: from pathogenesis to therapeutics

Contact Info

Product

Resources

About